VolitionRx Limited, a multinational epigenetics company trading on the NYSE American under the symbol VNRX, announced results from a clinical study showing high accuracy for its Nu.Q Vet Feline assay in detecting lymphoma in cats. The blood-based test achieved 100% specificity, meaning no false positives, while detecting more than 80% of feline lymphomas. This supports development of what the company expects to be the world's first simple and affordable liquid biopsy test for feline cancer.
Feline lymphoma represents the most common cancer in cats, and diagnosis has historically been challenging. Veterinarians typically rely on invasive biopsies or costly imaging procedures, often only after symptoms have progressed significantly. The company noted that veterinarians have sought a feline screening solution for years to enable earlier intervention. The Nu.Q Vet Feline Test aims to address this unmet need through a straightforward blood test that could become part of routine veterinary care.
The announcement follows VolitionRx's international rollout of its canine cancer test, demonstrating the broader applicability of its epigenetic technology platform across species. The company plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms. This approach could facilitate widespread adoption within veterinary practices.
VolitionRx is focused on advancing epigenetics science to save lives and improve outcomes for both people and animals with life-altering diseases through earlier detection and monitoring. The company develops simple, easy-to-use, cost-effective blood tests to help detect and monitor various diseases, including some cancers. Their research and development activities are centered in Belgium, with additional facilities in the United States and London. For further information about the company's work, visit https://volition.com/.
The implications of this development extend beyond veterinary medicine. Successful implementation of liquid biopsy technology in animal health could validate approaches for human applications, particularly in cancer screening where non-invasive methods are increasingly sought. For cat owners, an accessible screening test could mean earlier cancer detection, potentially leading to more treatment options and improved quality of life for their pets. The veterinary industry may see reduced reliance on expensive diagnostic procedures, making cancer screening more routine and affordable.
The study results were reported through BioMedWire, a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences developments. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides various distribution services for corporate communications. The full press release containing the study details can be accessed at https://ibn.fm/SI9RB. For more information about BioMedWire's services, visit https://www.BioMedWire.com.
